Key result
Sirolimus switch reduces aortic stiffness and central BP vs cyclosporine in renal transplant recipients.
Why the study?
Whether a cyclosporine A-free immunosuppressant regimen based on sirolimus prevents aortic stiffening and improves central hemodynamics in renal transplant recipients was unknown.
Does a sirolimus-based immunosuppressant regimen reduce aortic stiffness in renal transplant recipients compared to a cyclosporine A-based regimen?
RCT (n=44)
Blinded outcome assessment
Randomized
Does a sirolimus-based immunosuppressant regimen reduce aortic stiffness in renal transplant recipients compared to a cyclosporine A-based regimen?
A sirolimus-based immunosuppressant regimen reduces aortic stiffness, plasma endothelin-1, and oxidative stress in renal transplant recipients compared to cyclosporine A, suggesting a potential cardiovascular protective effect.
Answers are grounded in this paper and cite their sources.
Sirolimus-based regimens may reduce vascular stiffness in renal transplant recipients; extends RCT evidence for mTOR inhibitor benefits beyond standard immunosuppression.
Whether or not a cyclosporine A (CsA)-free immunosuppressant regimen based on sirolimus (SRL) prevents aortic stiffening and improves central hemodynamics in renal recipients remains unknown. Forty-four patients (48 ± 2 years) enrolled in the CONCEPT trial were randomized at week 12 (W12) to continue CsA or switch to SRL, both associated with mycophenolate mofetil. Carotid systolic blood pressure (cSBP), pulse pressure (cPP), central pressure wave reflection (augmentation index, AIx) and carotid-to-femoral pulse-wave velocity (PWV: aortic stiffness) were blindly assessed at W12, W26 and W52 together with plasma endothelin-1 (ET-1), thiobarbituric acid-reactive substances (TBARS) and superoxide dismutase (SOD) and catalase erythrocyte activities. At W12, there was no difference between groups. At follow-up, PWV, cSBP, cPP and AIx were lower in the SRL group. The difference in PWV remained significant after adjustment for blood pressure and eGFR. In parallel, ET-1 decreased in the SRL group, while TBARS, SOD and catalase erythrocyte activities increased in both groups but to a lesser extent in the SRL group. Our results demonstrate that a CsA-free regimen based on SRL reduces aortic stiffness, plasma endothelin-1 and oxidative stress in renal recipients suggesting a protective effect on the arterial wall that may be translated into cardiovascular risk reduction.
No takes yet. Share an insight, caveat, or question.
Joannidès et al. (2011) conducted an RCT in Renal transplant (n=44). Sirolimus (SRL) vs. Cyclosporine A (CsA) was evaluated on Aortic stiffness (PWV), central hemodynamics, and oxidative stress markers. Switching to a sirolimus-based regimen from cyclosporine A significantly reduced aortic stiffness, central blood pressure, and oxidative stress in renal transplant recipients.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: